Monday 1st July 2024 |
Text too small? |
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Anita Baldauf has announced her intention not to seek re-election and to retire as a director of the company at the upcoming shareholders meeting on Friday 2nd August 2024.
Chair David Flacks said: “On behalf of the Board, I would like to sincerely thank Anita for her valuable contribution and service during her four-year tenure. Her industry knowledge and international finance and marketing experience has been of great assistance to AFT particularly in its continued growth internationally.”
The Board will now commence a recruitment process for a replacement director, and further details will be announced in due course.
Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals (ASX:AFP, NZX: AFT )
www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors